Important regulatory information Not approved for human use BPC-157 is not approved by the FDA and is not a dietary supplement, drug, or food
That involves comparing the performance of a drug with that of a placebo
Last Updated: March 30, 2026 | Reading Time: Approximately 9 minutes | Author: Palmetto Peptides Research Team Quick Answer Retatrutide is supplied as a lyophilized (freeze-dried) powder
Patients should be educated about potential symptoms of thyroid tumors, including persistent hoarseness, difficulty swallowing, or a neck mass, though these symptoms are rare and may have many other causes
Loading Phase (Weeks 1 through 4) Tb-500: 2 to 2.5 mg twice weekly (Monday and Thursday) totaling 4 to 5 mg per week Bpc-157: 0.5 mg daily, either as single dose or split into 0.25 mg twice daily Maintenance Phase (Weeks 5 through 8 plus) Tb-500: 2 mg once weekly Bpc-157: 0.25 to 0.5 mg daily Critical Notes Use separate vials and syringes for each peptide Never mix Bpc-157 and Tb-500 in the same syringe Tb-500 can be injected anywhere subcutaneously Bpc-157 should ideally be injected near the injury site The critical implementation detail bears repeating: Bpc-157 and Tb-500 should never be combined into a single vial as peptides lose their effectiveness when mixed incorrectly
